首页> 外文OA文献 >Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin

【2h】

Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin

机译：将PAM4（clivatuzumab）（一种在临床试验中用于胰腺导管腺癌的早期检测和治疗的单克隆抗体）映射到MUC5AC粘蛋白

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
David V Gold; Guy Newsome; Donglin Liu; David M Goldenberg;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin [J] . David V Gold, Guy Newsome, Donglin Liu, Molecular Cancer . 2013,第1期

机译：将PAM4（clivatuzumab）（一种在临床试验中用于胰腺导管腺癌的早期检测和治疗的单克隆抗体）映射到MUC5AC粘蛋白
2. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells [J] . Yukari Nishii, Miki Yamaguchi, Yasutoshi Kimura, International journal of oncology . 2015,第4期

机译：新开发的抗Mucin 13单克隆抗体靶向胰腺导管腺癌细胞
3. Semiquantitative immunohistochemistry for mucin (MUC1, MUC2, MUC3, MUC4, MUC5AC, and MUC6) profiling of pancreatic ductal cell adenocarcinoma improves diagnostic and prognostic performance [J] . Sierzega Marek, Mlynarski Damian, Tomaszewska Romana, Histopathology: Official Journal of the British Division of the International Academy of Pathology . 2016,第4期

机译：胰腺导管细胞腺癌的黏蛋白（MUC1，MUC2，MUC3，MUC4，MUC5AC和MUC6）的半定量免疫组织化学分析可改善诊断和预后性能
4. Generation of Novel Anti-CLDN18.2 Monoclonal Antibodies as Therapies for Gastric and Pancreatic Cancer [C] . Richard Zhang, Haishan Lin, Andrew Wong, Protein Engineering Summit. . 2018

机译：生成新型抗CLDN18.2单克隆抗体作为胃癌和胰腺癌的疗法
5. Stroma-Targeting Therapies and Local Intervention in Pancreatic Ductal Adenocarcinoma [D] . Elahi-Gedwillo, Kianna Y. 2018

机译：胰腺导管腺癌的基质靶向治疗和局部干预
6. Mapping PAM4 (clivatuzumab) a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma to MUC5AC mucin [O] . David V Gold, Guy Newsome, Donglin Liu, 2013

机译：将PAM4（clivatuzumab）（一种在临床试验中用于胰腺导管腺癌的早期检测和治疗的单克隆抗体）映射到MUC5AC粘蛋白
7. Differentiation of Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis by PAM4 Immunohistochemistry [O] . Chanjuan Shi, Nipun Merchant, Guy Newsome, 2014

机译：PAM4免疫组化对慢性胰腺炎胰腺导管腺癌的分化

Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin

著录项

引文网络

相似文献

相关主题

期刊订阅